Article
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer.
Pharmacogenetics and genomics - 1 Jan 2021
Ingle James N, Kalari Krishna R, Barman Poulami, Shepherd Lois E, Ellis Matthew J, Goss Paul E, Buzdar Aman U, Robson Mark E, Cairns Junmei, Carlson Erin E, Eyman Casey Abraham, Hoskin Tanya L, Goodnature Barbara A, Haddad Tufia C, Goetz Matthew P, Weinshilboum Richard M, Wang Liewei
Abstract excerpt
OBJECTIVES: Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant anastrozole therapy had a three-fold risk of recurrence, we aimed to identify a single-nucleotide polymorphism (SNP)-based model that would predict elevated E1 and E2 and then validate it in an independent dataset....
Topics
Join the communities discussing this publication.